Stop TB partnership launches new global plan



The Stop TB Partnership has launched the Global Plan to End TB 2018-2022, which calls for 2.6 billion USD per year for vital research and development of new tuberculosis (TB) diagnostic tools, new drug regimens and a new vaccine, and 13 billion USD per year for TB care and prevention.

With the new Global Plan, the Stop TB Partnership is also launching the largest ever call for proposals, 2.5 million USD, to fund grassroot organizations as part of the TB response as well as new, child-friendly drug-resistant TB treatments.

Unlike previous five-yearly plans, the updated Global Plan for 2018-2022 is deliberately aligned to the time frame of the UN High-Level Meeting (UNHLM) on which TB targets and provides an estimate of the resources needed to achieve these targets.

The Global Plan , if fully funded and implemented, will enable countries reach UNHLM on TB treatment targets set for 2022, including putting 40 million people on treatment for TB, including 3.5 million children and 1.5 million people with drug-resistant TB.
This will lead to 1.5 million fewer deaths due to TB, and the return on investment will be 44 USD for 1 USD spent.

To achieve these goals, the partnership said 13 billion USD every year is needed globally for TB care and prevention—approximately twice the current level invested.

And 2.6 billion USD is needed every year for research and development of new diagnostics, new drugs and a new vaccine—approximately three times the current level invested.

According to the partnership, many countries will have difficulties reaching these funding levels. While high-income countries, BRICS (Brazil, Russia, India, China, and South Africa) and upper-middle-income countries can tap domestic budgets to reach the necessary funding levels, low-income and lower-middle-income countries will need increased external funding.

The Global Fund to Fight AIDS, Tuberculosis and Malaria provides nearly 80% of external funding for TB programs but the envelope provided is very small versus the actual needs, with a total of 840 million USD/year.

Pediatric- DR TB 
At the event, Stop TB’s Global Drug Facility (GDF) officially launched the Pediatric Drug-Resistant TB (DR-TB) Initiative.

Of the estimated 1.1 million children under the age of 15 who became sick with TB around the world in 2018, an estimated 32,000 had DR-TB. Of those, fewer than 5% are diagnosed and receive treatment. Even fewer of those under the age of five received treatment.
Until recently, only 500 young children globally with DR-TB received treatment, and those who were treated were put on medicines intended for use in adults.

Supported by USAID and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, each grant will be between 25,000 and 150,000 USD to cover 12 months of activities.

The call for proposals covers 14 high TB-burden countries: Bangladesh, Cambodia, DR Congo, India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, Philippines, South Africa, Tanzania, and Ukraine. It also covers the following regions: Anglophone Africa, Francophone Africa, Asia, Latin America and the Caribbean and Europe.

In 2018, ten million people fell ill from TB and 1.5 million people died from the disease, taking a huge toll on human and economic health in countries worldwide.

Roughly 30% of the new infections went undetected and unmonitored, however, and the TB epidemic will never be fully controlled until all infections are tracked and treated.
Bilkisu Pai